Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
NAVB
Navidea announces results from post-hoc analysis from Lymphoseek injection trial
Navidea Biopharmaceuticals announced results from a post-hoc analysis of patient data from the company’s Phase 3 clinical trial -- NEO3-06 -- of Lymphoseek in head and neck cancer. The ability of Lymphoseek to localize in sentinel lymph nodes is based on its ability to target specific CD206 mannose receptor sites in macrophages, a type of immune cell which resides in high concentration in lymph nodes. In the NEO3-06 Phase 3 study, Lymphoseek localization to lymph nodes showed a strong correlation with a full regional lymph node dissection and pathology analysis with a low false negative rate, a priority in identifying sentinel nodes. Lymphoseek was also observed to home preferentially to pathology-positive nodes at a higher rate than pathology-negative nodes. These results suggest that Lymphoseek not only effectively targets sentinel lymph nodes, but further that its ability to highlight tumor-positive lymph nodes may be augmented mechanistically by the recruitment of macrophages to cancer-harboring lymph nodes. The analysis, based on data from the Phase 3 clinical trial for Lymphoseek in head and neck cancer, evaluated 83 patients to determine whether Lymphoseek localization in pathology-positive lymph nodes was higher than its localization in pathology-negative nodes, and if those results were consistent with the overall sentinel lymph node population.
Re: Farmas USA
Muchos se habran puesto cortos , yo conozco alguno.
Y otros muchos habran vendido si venian de 2medios ...
ACHN